Lipids & metabolic liver disease
Nonalcoholic Fatty Liver Disease Incidence and Remission and Their Predictors During 7 Years of Follow-up Among Finns
Authors' conclusion
During follow-up, NAFLD developed for every fifth participant without NAFLD at baseline, and one-fifth of those with NAFLD at baseline had achieved NAFLD remission. NAFLD became more prevalent during the follow-up period. From a clinical perspective, key factors predicting NAFLD incidence and remission were BMI and WC change independent of their baseline level.
Study context
- Population
- Middle-aged general Finnish population, repeatedly studied, with liver US data and no excessive alcohol intake
- Participants
- 1,260 participants
- Exposure
- No nonalcoholic fatty liver disease (NAFLD) at baseline vs NAFLD at baseline
- No NAFLD at baselinen = 1,079
- NAFLD at baselinen = 181
- Outcome
- NAFLD incidence and remission (hepatic steatosis by liver US)
- Follow-up
- 7.2-year study interval
Methodological detailspopulation-based, 7.2-year study interval
- Population-based
- 7.2-year study interval
Main finding
As reported in the abstract
Developed NAFLD among 1079 without NAFLD at baseline
198
Achieved NAFLD remission among 181 with NAFLD at baseline
40
Observational data: associations, not effects.
Further findings
Predictors of incident NAFLD (accounting for multicollinearity)
- Baseline age, OR
- 1.07 (95% CI 1.02-1.13; P = .009)
- Waist circumference, OR per 1 SD (1.91-4.01; P < .001)
- 2.77
- Triglycerides, OR per 1 SD (1.53-3.51; P < .001)
- 2.31
- Alanine aminotransferase (ALAT), OR per 1 SD (1.20-3.00; P = .006)
- 1.90
- Body mass index (BMI) change, OR per 1 SD (3.02-5.63; P < .001)
- 4.12
Predictors of NAFLD remission
- Baseline aspartate aminotransferase (ASAT), OR per 1 SD (0.08-0.67; P = .007)
- 0.23
- Waist circumference change, OR per 1 SD (0.25-0.59; P < .001)
- 0.38
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →